WSJ
23 Jul 2026, 05:40 UTC · 1h ago
Roche Backs Full-Year View as First-Half Sales Rise
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
WSJ
23 Jul 2026, 05:40 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
2 claims · each scored for market impact
The drugmaker's sales exceeded analysts' expectations based on a company compiled consensus. — Beating consensus estimates typically triggers positive price action for the specific company's stock.
+0.60Sales grew 6% on a constant exchange rate basis. — Steady organic growth indicates healthy demand, providing a positive fundamental backdrop for the asset.
+0.30Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Continue reading
6 related stories
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Reuters
1h ago
